|
|
|
|
| LEADER |
03606nam a2200349 u 4500 |
| 001 |
EB001865288 |
| 003 |
EBX01000000000000001029368 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
190504 r ||| eng |
| 245 |
0 |
0 |
|a Pharmacoeconomic review report: Nitisinone (Orfadin) (Sobi Canada Inc.)
|h Elektronische Ressource
|
| 246 |
3 |
1 |
|a Nitisinone (Orfadin) (Sobi Canada Inc.)
|
| 246 |
3 |
1 |
|a CADTH common drug review pharmacoeconomic review report for nitisinone (Orfadin)
|
| 260 |
|
|
|a Ottawa (ON)
|b CADTH
|c 2018, April 2018
|
| 300 |
|
|
|a 1 PDF file (29 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Tyrosinemias / diet therapy
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Nitrobenzoates / economics
|
| 653 |
|
|
|a Administration, Oral
|
| 653 |
|
|
|a Tyrosinemias / drug therapy
|
| 653 |
|
|
|a Cost-Benefit Analysis
|
| 653 |
|
|
|a Nitrobenzoates / therapeutic use
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK533442
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 330
|
| 520 |
|
|
|a Although nitisinone can be used in both pediatric and adult populations, the manufacturer's economic evaluation is based on a subset of the labelled indication: the treatment of newborns who are identified and treated within one month of birth, either through a newborn screening program or through physical examination, patient history, and specialized tests (including urine succinylacetone levels). The submitted cost-utility analysis compares costs and health benefits associated with nitisinone 1 mg/kg plus best supportive care (BSC; dietary restriction) versus BSC (dietary restriction) alone in the treatment of newborns at least one month old, from a health ministry perspective. The model is based on three health states: diagnosed with HT-1; liver transplant with associated tunnel states; and dead. The time horizon was a patient's lifetime (100 years), and future costs and benefits were discounted at 1.5% annually.
|
| 520 |
|
|
|a Nitisinone (Orfadin) is indicated for the treatment of patients with hereditary tyrosinemia type 1 (HT- 1) in combination with dietary restriction of tyrosine and phenylalanine. Nitisinone is available as 2 mg, 5 mg, 10 mg, and 20 mg capsules for oral administration. The submitted price of nitisinone is based on dose: 2 mg ($22.50), 5 mg ($53.30), 10 mg ($100), and 20 mg ($193.33). The recommended initial dosage in pediatric and adult populations is 1 mg/kg body weight daily divided in two doses administered orally. If plasma or urine succinylacetone is still detectable one month after starting treatment, the dosage should be increased to 1.5 mg/kg daily to a maximum dosage of 2 mg/kg daily. If the biochemical response is satisfactory, dosage should be adjusted only according to body weight gain.
|
| 520 |
|
|
|a Comparative treatment effect was based on assumptions regarding premature mortality taken from a study of a Quebec-based cohort (Larochelle et al.) of newborns followed for up to 14 years. Utility values were derived from a cohort of men (average age 54 years) with decompensated cirrhosis resulting from chronic hepatitis B infection and measured with the Health Utility Index Mark 3 (HUI3) instrument. Assumptions regarding resource use and costs were derived from a Quebec-based study of HT-1 patients as well as a British Columbia-based study of liver transplantation costs
|